SAN FRANCISCO – DecisionView, Inc., a leading provider of software solutions to optimize clinical trial enrollment for life sciences companies, today announced that the board of directors has appointed Linda Drumright as president of the company. In addition, she will continue to represent DecisionView as COO, a position she has held since 2005. Jim Scullion, DecisionView’s CEO, will assume the position of executive chairman and continue in his role as Chairman of the Board.
"We are fortunate to have Linda Drumright as our new president because she has played a broad and important role in driving our strategy over the years, and has shown even greater skill and leadership in executing that strategy," said Scullion, who, in addition to his new role at DecisionView, will be serving as CEO-in-Residence with Granite Ventures, one of DecisionView’s investors. "Linda has been a great partner to me, and I am looking forward to continuing my collaboration with her, the DecisionView team and the company's board. I'm proud of all that we've accomplished over the past 12 months during this exciting stage of the company's development, and together we can ensure that DecisionView achieves its full potential."
Drumright joined DecisionView in 2005, and has been responsible for all products, services and business operations at the company. She brings more than 27 years of experience in building commercial software products, with a strong focus on delivering market-leading performance optimization software products and services to meet the needs of life sciences customers. Before joining DecisionView, Drumright provided management consulting services to the company and several emerging enterprises and venture capital firms. Prior to this, she ran product development and delivery at a number of leading software companies, including DigitalThink, Hyperion, Arbor Software and Sybase. Drumright earned a Bachelor's of Arts degree in Computer Science from University of California, Berkeley, and completed the Haas School of Business Executive Program.
"Now is an incredibly important time for DecisionView and I am thrilled to be leading the execution of our strategic vision," Drumright added. "We have a terrific opportunity to capitalize upon our success with StudyOptimizerTM to build a highly valuable business in the emerging clinical trial enrollment optimization space. It has been a great privilege to work with and learn from Jim over the past 12 months, and that partnership will serve us well as we focus on the opportunities and challenges ahead."
